clinical trial | Q30612 |
P3098 | ClinicalTrials.gov ID | NCT00259857 |
P6099 | clinical trial phase | phase II clinical trial | Q42824440 |
P17 | country | United States of America | Q30 |
P582 | end time | 2008-03-01 | |
P4135 | maximum age | 15 | |
P1050 | medical condition | osteoporosis | Q165328 |
P2899 | minimum age | 5 | |
P1132 | number of participants | 22 | |
P4844 | research intervention | calcium oxalate | Q412399 |
(5R)-24,25-Dihydroxyvitamin D | Q27161510 | ||
alendronate sodium trihydrate / colecalciferol | Q28859601 | ||
P6153 | research site | Medical University of South Carolina | Q6806451 |
P580 | start time | 2003-10-01 | |
P8363 | study type | interventional study | Q78089383 |
P1476 | title | A Randomized, Double-Blind, Placebo-Controlled, Prospective, Cross-Over Phase II Clinical Trial to Determine the Safety and Efficacy of Alendronate (Fosamax) in Juvenile Osteoporosis (IND#60,017) |
Search more.